MicroTech Medical (Hangzhou) Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

MicroTech Medical (Hangzhou) (HKG:2235) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥345.6m (up 37% from FY 2023).
• Net loss: CN¥63.1m (loss narrowed by 50% from FY 2023).
• CN¥0.15 loss per share (improved from CN¥0.29 loss in FY 2023).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

MicroTech Medical (Hangzhou) EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 1.8%. Earnings per share (EPS) exceeded analyst estimates by 21%.

The primary driver behind last 12 months revenue was the Mainland China segment contributing a total revenue of CN¥236.7m (68% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to CN¥207.1m (66% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of CN¥68.6m. Explore how 2235's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in Hong Kong.

Performance of the Hong Kong Medical Equipment industry.

The company's shares are down 3.8% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on MicroTech Medical (Hangzhou)'s balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.